Hydrogen Water Reduces Keloid Scars and Pain in New Clinical Trial
- Authors
- Xinwen Kuang, Zhengyun Liang, Mengjie Shan, Yan Hao, Yijun Xia, Chao Xia, Hao Liu, Qiao Chen, Guojing Chang, Qianjun He, Youbin Wang
- Journal
- Aesthetic Plastic Surgery
- Year
- 2026
- DOI
- 10.1007/s00266-025-05512-5
- Study Type
- Human
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- China
- Health Condition
- Keloids
- Body System
- Integumentary
TL;DR
Hydrogen-rich water reduced pain, itching, and inflammation in keloid patients by improving inflammatory and tissue-repair signaling.
Key Finding
Keloid patients who drank hydrogen-rich water reported significantly less pain and itching, and showed reduced inflammatory markers and improved scar appearance compared to the control group.
Summary
This small pilot study tested whether drinking hydrogen-rich water could help patients with keloids (thick, raised scars) feel better and reduce inflammation. Twenty-one keloid patients were randomly assigned to drink either hydrogen-rich water or regular water for an unspecified period. Patients drinking hydrogen-rich water reported less pain and itching, and their scars showed improvement on clinical measures. Laboratory tests showed that hydrogen-rich water reduced inflammatory markers (chemical signals that promote inflammation) and increased anti-inflammatory markers.
Practical Takeaway
This is a small pilot study (21 patients) that suggests hydrogen-rich water may help reduce keloid symptoms and inflammation, but the results are preliminary. The study duration and exact dosing were not reported, making it difficult to know what dose or timeline might be relevant. Much larger studies are needed before hydrogen-rich water can be recommended as a keloid treatment.
Abstract (excerpt)
Background: Clinical or experimental trials have shown that hydrogen-rich water has anti-inflammatory properties, but its use for keloids has not been studied. This research explores HRW's therapeutic potential and mechanism for keloid treatment. Methods: 21 keloid patients scheduled for two-stage…